|
| |
BioJournal -
Kalorama Market Research
http://www.bioportfolio.com/cgi-bin/acatalog/Kalorama.html
 |
While insurance is the most common form of payment for healthcare
services, increasingly customers are paying for their own expenses.
Pharmaceutical, device and diagnostic companies, should recognize that a
part of their revenues are originating directly or indirectly from out of
pocket expenditures. Health care costs are high and accelerating as a result
of a confluence of factors within the broader economy, as well as the health
care marketplace. Unique financial services have been created to facilitate
non-insurance-paid health care services, and more are expected to be created
in the near term. |
|
|
Although much of medicine is focused on the increased aging of the
population, children still represent the bulk the dependent population
worldwide. Important regulatory factors are also at work in the pediatric
pharmaceutical market. The recognition of the rights of children to have
access to safe and effective drugs and the needs of healthcare providers to
have access to age-appropriate drug information continues to have a major
effect on all areas of pediatric pharmaceuticals including pediatric
biomedical research. |
|
|
Offshoring of clinical trials is increasing as companies in the U.S. are
finding challenges in clinical trial research ranging from cost, patient
recruitment, patient compliance during participation, qualified
professionals, new clinical trial patients, and other problems. This
provides an opportunity for developing regions to grab a piece of the
clinical trial market. |
|
|
Contract Manufacturers are finding opportunities with managers located at
OEM corporate headquarters or main manufacturing/assembly operations as they
take a hard look at costs and seek outsourcing for cost efficiency. |
|
|
Cell analysis is not a new laboratory procedure. Clinical diagnostics
using cells and tissues is one of the oldest disciplines in laboratory
medicine. Histological study of biopsy samples, the complete blood count,
and the enumeration of disease-bearing cells have been used routinely for at
least 60 years. In many ways, these disciplines had changed little until the
1990s. What's new, however, is the myriad of combinations of tests and
technologies that come together to create a new map of cell diagnostics.
|
|
|
Analytical microchips can be considered one of the fastest growing
technology segments in life sciences. The range of applications to which
these miniature laboratories may be directed is very broad — covering fields
as different as pharmaceutical development, food testing, clinical
diagnostics, forensics, and environmental analysis. |
|
|
As one of the most competitive pharmaceutical markets, keeping track of
the cardiovascular drug market can be a difficult undertaking. The range of
therapeutic options available to physicians has expanded significantly in
the past few years, and will continue to increase with a robust pipeline.
Kalorama's 2nd edition of The World Market for Cardiovascular Drugs
Market is designed to steer marketers through the sheer size and
diversity of the current market and the potential of new products that will
make this therapeutic category among the most competitive of prescription
drug segments. |
|
|
For food ingredient companies willing to enter the non-food market,
there is over a billion dollars of market potential awaiting them. In
addition to increasing the profitability of their traditional product lines,
producers of ingredients can potentially expand their markets by moving
their products or byproducts into the healthcare sector, where drug
producers or manufacturers of some biomedical devices could incorporate them
into their products. |
|
|
Abundant opportunities are available for manufacturing companies who
enter the outsourcing medical device manufacturing market; but the market is
competitive and information has been hard to obtain. Original equipment
manufacturers (OEMs) are finding opportunities with managers located at the
corporate headquarters or main manufacturing/assembly operations as they
take a hard look at costs and seek outsourcing for cost efficiency.
Kalorama's OEM Contract Manufacturing in Medical Devices Series presents a
total study of market for outsourcing in medical devices. It features an
exhaustive three-way market segmentation: It looks at the OEM market
revenues by therapeutic area, as well as by segment of device manufacturing.
And it also includes revenues by the general device classifications
(commodity/non-commodity). This allows those looking at this growing market
to get a complete picture of the OEM market.
|
|
|
Retail clinics, also known as convenience clinics, represent a
disruptive innovation into the U.S. health care market, which evolved from
and is uniquely positioned to benefit from the health care system’s
shortcomings.
These clinics present a new opportunity for retail outlets to earn more
revenue from rents and 'indirect' revenues from sales to the retail store as
a result of a clinic visit. But there is also an opportunity for diagnostic
and pharmaceutical companies to capitalize on this trend. |
|
|
In five years, Kalorama Information believes the role of pharmacists
currently and the demands of the US healthcare system, pharmacists will be
prescribing in at least six states in five years, creating a trend that will
spread to many other states in following years. The state of Florida allows
some independing prescribing off an approved list, and many states allow
prescription choice from a physicians diagnosis. The cost of copays and the
time spent on doctor visits will increase demand for drug decisions to be
made at the pharmacist level.
This report, Prescribing Pharmacists, a Decision Maker Emerges details the
reasons behind this change and defines the roles of the new decision makers
that pharmaceutical companies will have to incorporate into strategy. In the
U.S. healthcare market the role of the pharmacist is changing. This report
details the tremendous transformation occuring. |
|
|
Drug pricing is one of the key levers that determine the profitability
of a drug company. Premium pricing of a new drug helps cover the high cost
of innovation and helps run a profitable enterprise. But the recent
onslaught of generics, as well as shrinking government and corporate
healthcare budgets, is threatening the time-tested models, leading to higher
pricing pressures for pharmaceutical and biotech companies in the coming
years. In this environment, executives in these companies and the
consultants who service them need better information to make the most
profitable decisions. |
|
|
Orthopedic biomaterial products, which can be organic or synthetic in
nature, are implanted into or near a bone fracture to facilitate healing or
to compensate for a lack or loss of bone tissue. Biomaterials used in
orthopedic surgery include autografts, allografts, xenografts, ceramics,
polymers, bone growth factors and synovial fluid substitutes. Among the
prominent applications for orthopedic biomaterials are surface coatings for
hip prostheses, bone cements, bone defect fillers, and fracture fixation
plates. |
|
|
There are millions of surgical procedures performed annually worldwide
and the market for wound care products and techniques is significant. In the
United States alone, there are over 100,000 surgeries performed daily.
Surgical and trauma wounds are, by far, the most common types of wounds
addressed in the wound care area. |
|
|
The aging of the population and continued advances in biotechnology
drive the multi-billion dollar wound care industry globally. Besides the
always-improving synthetic dressing materials, newer technologies in wound
treatment include the xenogeneic tissue scaffold, bilayered human dermal
substitutes, recombinant growth factors, endoscopic subfascial ligation of
venous perforators, and endovascular arterial repair techniques. |
|
|
The world market for OEM Contracting in the Manufacturing of Medical
Devices is exploding as original equipment manufacturers are finding new
opportunities with managers located at the corporate headquarters or main
manufacturing/assembly operations continually reviewing manufacturing costs
and looking to outsourcing for cost efficiency. |
|
|
This Kalorama Information report - Clinical Nutrition Products: The
World Market, represents the second time that Kalorama Information has taken
a comprehensive look on the medical nutrition market in three segments:
Infant Nutrition
Enteral Nutrition
Parenteral Nutrition |
|
|
The unrecognized importance, danger and costs of hepatitis in the 21st
century cannot be understated or underestimated. While we were fortunate
that, in the latter part of the 20th century, in that hepatitis was fairly
well held in check, the impact of the disease on world society is still
highly significant and now presenting a major crisis in public health
circles. |
|
|
The use of virtual reality (VR) technologies in the healthcare field is
not simply a far-away future possibility. Technologies are already in place
and the benefits from the application of VR are already evident in the
healthcare domain. These applications provide doctors an opportunity to
perform tasks in a risk-free environment, and make training accessible for a
large number of students as the apprenticeship of experienced doctors is not
necessary. Additionally, VR simulators allow medical professionals to remain
abreast with the latest technical procedures required in the profession. |
|
|
The number of procedures requiring anesthetic administration continues
to climb with the growing and aging population in many regions of the world.
The population of the world plays an important role in the growing incidence
and prevalence of disease and will reflect positively on growth for
anesthesia drugs. |
|
|
The trend toward cost-effective skin ulcer treatment remains embedded in
management programs that emphasize prevention and early intervention. New
wound care products and devices are entering the market with lightening
speed, all striving for the best clinical outcomes. |
|
|
In light of laboratory pressures to do more with less, laboratory
managers transfer cost control onto vendors by means of a constant push for
price reductions. In this commercial climate, efficient management of
customer and technical service extras is critical. Expertise in managing
service offerings will help companies offer service programs that are just
enough to differentiate them from the competition. Service programs that
offer too much may result in revenue loss. Programs that are perceived to be
inadequate place the company at a competitive disadvantage. |
|
|
DNA sequencing can be defined as any biochemical method for determining
the order of the nucleotide bases, adenine, guanine, cytosine, and thymine,
(A,G,C,T) in a DNA nucleotide. DNA Sequencing has accelerated research and
discovery, which created a brisk market for sequencing systems that perform
this work. That market has been relatively stable for the last several
years, with a dominant vendor, Applied Biosystems, and relatively few
changes taking place in the products or technologies. |
|
|
Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS
that causes significant disability in young adults. Worldwide, millions of
people are affected by multiple sclerosis. Although there is no cure,
approved treatments are available to slow the progression of MS and offer
improved quality of life.
The market for these treatments has grown 15% since 2004 and continued
double-digit growth is expected in the near term. Kalorama Information's:
Multiple Sclerosis: A Market Briefing takes a detailed look at multiple
sclerois worldwide and the market for MS treatments, as well as treatments
that will be available in the future. |
|
|
Toxicity is a crucial parameter that is measured throughout the drug
development process. Toxic side-effects are one of the most common reasons
drug candidates fail. Toxicity can be a factor of dose, the form in which
the drug is administered, and the time of exposure before elimination.
Patient responses also differ widely, depending on their age and metabolism
and other products in the patient’s system may augment the effect of the
drug.
Just twenty years ago, toxicology was something that was measured after a
drug was developed. Traditional studies were performed in-vivo with animals,
and required 20 to 100 grams of the candidate compound for a single set of
evaluations. Intake of the compound was measured, and a series of toxicity
tests were performed, including LD 50 and histological examinations of
target organs. These tox tests were expensive, time-consuming and were only
performed on drug candidates that had already passed all other criteria to
become successful drugs. These studies were high information, but low
throughput estimates of a candidate drug’s toxicology. Failures were common,
and expensive. The goal was to find approaches that would predict toxicology
at an earlier stage, and with less cost. |
|
|
The importance, danger and costs of tuberculosis in the 21st century
cannot be understated or underestimated. Though nearly extinct in the 20th
century, Over 1.6 billion people worldwide suffer from tuberculosis, and it
is now presenting a major crisis in public health circles.
In addition to the basic pathology and complications of tuberculosis, there
are primarily three focal points for the development of strategy in this
area: potential market, epidemiology (tuberculosis patient trends) and
technology. |
|
|
RFID (Radio Frequency IDentification) technologies are dramatically
changing many industries, but as detailed in Kalorama's market research
report RFID Opportunities in Healthcare in the U.S., the greatest market for
RFID is in healthcare. Hospitals, pharmaceutical companies, nursing homes,
and other healthcare entities will benefit from using the technologies to
keep track of inventories and patients. |
|
|
Although Asia Pacific was the smallest healthcare market as of 2006, out
of the three major geographic regions (US, Europe, and Asia Pacific),
continued growth makes it an important ancillary market for makers of
medical devices. |
|
|
This study U.S. Market for Home Care Products, 5th Edition represents
the fifth time Kalorama Information has investigated this growing market
over the past 12 years. The U.S. market for home care products and equipment
continues to post steady gains, primarily as a result of the aging
population and increasing shifts of chronic care patients from hospitals to
home. Serious market watchers will want to keep aware of trends in this
industry, movers and shakers as well as market data. |
|
|
Many in the clinical and manufacturing community have their eyes on the
Physician Office Laboratory (POL) as an outlet both to improve patient
compliance and outcomes and to open new market opportunities. Studies are
emerging on the clinical outcomes and cost-benefit of nearer-the-patient
testing, but little certain is known about POLs as a distribution channel
for diagnostics products. |
|
|
Molecular imaging maps the locations of specific molecules and
biomaterials within living tissue. As such, it has the potential to diagnose
a disease, to monitor the course of that disease, and possibly facilitate
treatment. Molecular imaging has developed into a promising new strategy for
the diagnosis, evaluation and treatment of disease. |
|
|
This series provides total coverage of the Anti-Infectives market, a
market that is changing due to product development resistance issues and in
some cases, generic competition.
Antifungals
Antibacterials
Antivirals
As part of its comprehensive coverage, each report includes:
Epidemiology including Incidence Statistics for each type of infection.
Current Market Size and Revenue Forecasts for each market segment to assist
with long term planning.
Discussion of Competitive Products in the market and new products in the
delivery pipeline.
Coverage of Generic Threats for affected major products.
Round-Up of the Key Players in each area of anti-infectives.
Over 195 Tables and Figures for easy access to information and decision
support tools, internal emails, memos and presentations.
Discussion of Unique Issues and Emerging Trends for each antibiotic area.
Market Share of Leading Competitors for each area.
U.S., Europe, Japan and Rest of World market data.
Product managers, marketing directors, business development executives in
the pharmaceutical industry and financial and consulting company executives
who invest in or serve this industry are among those who will find this
report a useful resource. |
|
|
This third volume of Kalorama Information’s World Market for
Anti-Infectives series, the 2nd. Edition focuses on three general product
segments of antiviral treatment:
Nucleoside Analogs
Protease Inhibitors
Other Misc. Antivirals
The report covers both currently marketed and late stage development
antiviral products in detail. For each segment, the report provides:
Revenue Data by Infection Type
An overview of products on the market
Review of products in the development pipeline
Market estimates and forecasts through 2011
Market segmentation by geographic region
Market share of leading suppliers
Market share of leading products
The report also includes statistical (epidemiologic and demographic)
information for viral infections by type worldwide, with special emphasis on
the United States and describes the major clinical, business, and regulatory
trends shaping the global and domestic markets.
The information for this report was gathered using both primary and
secondary research including comprehensive research of secondary sources
such as company literature, databases, investment reports, and medical and
business journals. In addition, Kalorama Information conducted interviews
with key industry officials, consultants, health care providers, and
government personnel. These sources were the primary basis in gathering
information specifically relating to revenue and market share data presented
in this report. Specific interviews with pharmaceutical company
representatives included marketing directors, division managers, and product
representatives. |
|
|
Cancer is the second most common cause of death in the industrialized
world. At this time, treatment for cancer focuses on some combination of
surgery, radiation, and chemotherapy.
But over the next five years, treatment is going to dramatically change. as
detailed in the report Monoclonal Antibodies, Vaccines and Other Immunologic
Cancer Treatments: World Market from Kalorama Information. One of the most
promising new approaches in modern cancer treatment is immunotherapy, the
development of methods to augment and enhance the body’s natural tendency to
defend itself against malignant tumors without damaging healthy tissue.
Immunological and biotherapy treatments which target therapy are a fraction
of total cancer treatment revenues at the current time, but will soon make
up the lion’s share of the total cancer therapy market. |
|
|
New biological treatments are being developed at a record place, but
their potential could be compromised by significant obstacles to delivery of
these drugs into the body. Pharmaceutical delivery is now nearly as
important as product. New systems are being developed, and Kalorama's Drug
Delivery Markets Series covers these new systems. |
|
|
Part of a three volume series.
Over one billion people suffer from fungal infections worldwide. Although
athlete's foot, dandruff, vaginal yeast infection and fungal nail are the
most common, there has been a steady increase in the incidence of more
serious infections. This is partially due to the widespread use of
antibiotics, which eliminate or decrease fungi-killing bacteria. Another has
been the increased number of individuals with reduced immune responses
caused by AIDS or the effects of chemotherapy. These are part of the factors
that have lead to nearly 6-billion dollar antifungal drug industry. |
|
|
This report includes all four volumes of Kalorama's 2nd edition of its
Drug Delivery Markets series, covering all major types, including:
Oral Delivery
Implantable/Injectable
Pulmonary
Transdermal/Transmucosal |
|
|
Since the advent of LASIK nearly two decades ago, refractive vision
correction remains a vibrant market impacted by technology. Kalorama's
market analysis takes a look at the entire market for non-disease eye
treatment procedures. Complete coverage of the vision correction market,
including the correction of conditions such as myopia (nearsightedness),
presbyobia (an inibility to focus), astigmatism and hyperopia or
far-sightedness. |
|
|
Smoking cessation is an increasingly important area of focus for
pharmaceutical companies, healthcare entities and governments. There are 1.4
billion smokers in the world, and with smoking is a known cause of heart
disease, lung cancer, respiratory infections and many other diseases. This
has created a large market for smoking cessation aids. |
|
|
The market for diabetes-related products is huge and continuing to grow.
However, it is not the same market as it was just 3 years ago. New trends in
care, new products (both therapeutic and diagnostic), new approaches to
long-term complications, and changing public health priorities and
geographic variations are shifting the sands of opportunities in diabetes
care. |
|
|
Contrast agents and radiopharmaceuticals have revolutionized in vivo
imaging. Technical developments in contrast media and imaging techniques is
combining with the trends toward both the functional and molecular
understanding of disease to create a rapidly growing marketplace in these
agents. |
|
|
The lungs are considered by many to be the best alternative for drugs
needing to bypass the gastrointestinal tract. With advancing technology, the
practice of utilizing the huge surface area of the lungs to delivery drugs
into the blood circulation has been slowly transforming into reality. |
|
|
Molecular diagnostics (also known as nucleic acid testing) has emerged
as a field that promises to renew technological progress in the clinical
laboratory and to vastly improve patient care. Although it has been a slower
than anticipated adoption in the clinical laboratory setting, molecular
diagnostics has begun to overcome the impediments of incomplete genetic
knowledge, the development of new technology platforms, and the
communication of their use and efficacy to lab personnel and clinicians
alike. |
|
|
Few pharmaceutical markets will see the dramatic change that will occur
in cancer therapeutics over the next four years. More than $8 billion
dollars worth of new products are expected in the next four years, impacting
the treatment of cancer in ways that product managers, strategic planners,
business development managers and marketing executives will need to be aware
of. |
|
|
Fueled by the promise of needle-free mechanisms for vaccine distribution
and other pharmaceutical uses, the implantable/injectable drug delivery
market is growing rapidly. The development of better delivery systems in
conjunction with the discovery of novel pharmacological compounds will lead
to continued growth. |
|
|
In the next few years, U.S. hospitals, health systems and group
practices have earmarked billions for the purchase of technologies that will
help them improve efficiencies and reduce costs. Electronic Medical Record
(EMR) technology will certainly be among their purchases.
EMR has proven it can make healthcare workflow more efficient, reduce costs,
while at the same time improving the quality of patient care. Given these
undisputable benefits, the 1.2 billion-dollar market for EMR is expected to
grow nearly 400% in the next eight years, according to Kalorama’s experts.
|
|
|
Wireless technologies and healthcare are a perfect fit. The clinical
environment is a highly mobile one, and physicians, nurses and other
clinical operators have a real need for fast information and action. With a
record of successful implementations across aspects of healthcare from
patient care to sales, wireless technologies have moved from conjecture to
reality. Hospitals are dedicating large portions of current and future
budgets to IT development and wireless is likely to be among their choices.
Given these trends, Kalorama expects the 1.7 billion dollar wireless
healthcare market to grow to four times its current size by the end of the
decade. |
|
|
Lateral flow tests, also known as immunochromatographic strip (ICS)
tests, offer dramatic benefits in the diagnostic process that point towards
a robust market. LF tests reduce the time spent waiting for test results
from hours to minutes, require less training for operators, and reduce the
cost of both device development and manufacturing. |
|
|
Molecular diagnostics has emerged as a field that promises to renew
technological progress in the clinical laboratory and to vastly improve
patient care. Although it has been a slower than anticipated adoption in the
clinical laboratory setting, molecular diagnostics (also called nucleic acid
testing) has begun to overcome the impediments of incomplete genetic
knowledge, the development of new technology platforms, and the
communication of their use and efficacy to lab personnel and clinicians
alike. |
|
|
The current population of India is 1.065 billion, and with a growth rate
of 1.7%, India will surpass China to become the world’s largest country
around 2030. For diagnostic manufacturers, this enormous market is just now
being recognized as a high-growth area as the pace of economic growth in
India accelerates and modern laboratory practices become established. |
|
|
With a growing elderly population, premium pricing, and growing new
venues for sales, the kidney dialysis and dialysis equipment market
approaches $55 billion worldwide and is expected to grow. With those
revenues coming from just 1.6 million patients worldwide, kidney dialysis
and equipment is among the most lucrative markets in per-capita terms. |
|
|
What are the trends that are fueling a new boom in vaccine production
and sales? Why is an industry so commonly associated with children finding
an increasing marketplace among adult populations? What makes this class of
drugs likely to grow at a faster rate than other pharmaceutical products?
These are among the questions answered in Kalorama’s in-depth report,
Vaccines: The World Market. |
|
|
The market for psychotherapeutics drugs is about to change dramatically --
and serious pharmaceutical market watchers will want to be prepared.
Kalorama’s World Market for Psychotherapeutic Drugs is the most exhaustive
guide available to this booming market and the direction it is headed in the
next four years.
Psychotherapeutics treat conditions classified as abnormal behavior,
thoughts and feelings that persist for a determined amount of time causing
distress or emotional/physical impairment. Depression, anxiety, psychosis,
ADHD and nicotine and drug dependence are among the conditions
psychotherapeutics treat. Well-known brands such as Prozac™, Zoloft™ and
Ritalin ™ have made this a $37 billion market. And according to Kalorama’s
research, revenues from this area will grow more than 50% by 2010. |
|
|
The oral drug delivery market is the largest segment of the drug
delivery market, and there’s no sign that it is slowing down. With
pharmaceutical companies increasingly turning to drug delivery to extend the
revenue-earning lifetime of their biggest products, find a convienient form
and market acceptance of new biopharmaceuticals, and tap into the growing
elderly population that requires products with a level of ease-of-use and
cost benefit, it’s no surprise that the oral delivery drug market is a $35
billion industry and expected to grow as much as ten percent per year. |
|
|
Since more than 11 million Americans report pain as a significant
disability, there’s no question that pain management is big business for
healthcare practitioners today, and one area that market watchers need to
understand. When viewed globally, there is a large underserved population
for pain management medications, which indicates growth in what is now a 26
billion-dollar plus industry. |
|
|
In the pharmaceutical industry, cell culture is a major foundation of
biopharmaceutical development, bioprocessing and manufacturing.
Biopharmaceutical products are developed from large, complex protein
molecules, which require equally complex manufacturing methods and an array
of analytical techniques. As growing cells for biopharmaceutical production
is slow, expensive and complicated, optimizing cell culture development is
of paramount concern to companies developing biopharmaceuticals. |
|
|
Personalized medicine, the use of therapies that are targeted to the
individual patient, is a reality today, thanks to a growing emphasis on
biomarker research. Biomarkers are anatomic, physiologic, biochemical or
molecular parameters that are associated with the presence and severity of
specific diseases and illnesses. Biomarkers promise a smoother integration
of diagnostics and therapeutics, and most importantly a reduction in time
and cost for Phase I and II clinical trials. |
 |
Collectively, the techniques of photon-based experimental manipulation
and advanced optical imaging define the field of biophotonics. There are
several key areas that are associated with biophotonics. All of these center
on microscopy and related technology. The reason that this is so is that
biophotonics look at biological functions at the cellular level, or even
smaller. The only way that these processes can be observed is via one or
another form of microscopy. |
|
|
This report takes a bold look into the markets, technologies, and trends
in decentralized testing with a special focus on the economics of rapid test
use in critical care and emergency medicine. There is also an emphasis on
early disease detection via rapid test use in clinics and public venues. The
report is conservative in its predictions and offers a calculated look into
the future, based on events currently taking place. |
|
|
Protein biomarkers have become the hot application area for mass
spectrometry (MS) and other proteomics-related technologies in the last few
years. In the short term, this move towards biomarkers and clinical
proteomics research has happened mainly in the drug discovery and
development process. However, they also have broad abilities to generate
richer information about a disease state, drug response, and/ or the
relation between the two; which can be used for diagnostic, prognostic, or
various other purposes in the pharmaceutical, diagnostics, and defense
industries. |
|
|
Propelled by advances in molecular biology, the cancer vaccine industry
is poised for unprecedented growth. This second edition of Kalorama’s
groundbreaking 2003 study completely updates the market data and reviews the
technological, clinical, and business trends that have shaped and reshaped
this emerging field. |
|
|
Despite troublesome safety problems with past entrants into this market,
the veritable epidemic of overweight and obesity continues to make this
sector an extremely attractive target for pharmaceutical developers. This
new title provides a considered view of the market for medical interventions
in the battle against obesity, including U.S. and worldwide market size and
growth forecasts, competitive market share and extensive pharmaceutical
pipeline information. |
|
|
With the incidence of cardiac disease on a constant growth curve, a test
modality that can provide specific, inexpensive screening tools for
cardiovascular disease (CVD) before the onset of symptoms, is like the
proverbial "license to print money," and a large menu of tests have been
developed, including serum lipids, hypercoagulation factors, enzyme and
protein markers, genetic makeup, and even tests for certain viral
infections. |
|
|
Ultrasound, also known as sonography, is not a new imaging
modality—having been around since the 1950s—but its application areas have
just recently begun to expand tremendously. These new clinical applications,
along with technological innovations in portability and resolution and a
very favorable risk profile, have made ultrasound equipment a very robust
market sector. |
|
|
The orthopedic drug market is a highly competitive market and, in some
areas, the competitive environment is being shaped by increasing levels of
generic competition. Several large pharmaceutical companies compete in the
orthopedic drug market, including Abbott, Eli Lilly, GlaxoSmithKline, Merck,
Novartis, and Pfizer among others, and several other suppliers, such as
Serono, NovoNordisk, Amgen, and Genentech are developing or offering
products in more niche market areas. |
|
|
The global market for prescription respiratory drugs encompasses a wide
variety of products that treat both common everyday respiratory illnesses as
well as serious chronic conditions such as COPD. Technological developments
and improved delivery methods have given many health professionals a wider
range of products to treat patients with respiratory diseases and have
expanded the market for respiratory pharmaceuticals. |
|
|
This report focuses on the applications of current and advanced
therapeutics to the treatment of psoriasis and psoriatic arthritis, the
options they present, and the progress that is being made in these fields.
The major market effects of new therapeutics, with the potential of a
breakthrough drug always a possibility, are expected to be seen over the
next ten years. |
|
|
This report is focused on two expanding pharmaceutical outsourcing
markets, contract manufacturing and contract sales and marketing. Both
markets represent excellent post launch outsourcing opportunities for
companies competing in this fast growing pharmaceutical outsourcing sector. |
|
|
This comprehensive evaluation of the blood industry provides an analysis
of all the key market segments involved in this industry, including blood
products such as: Red Blood Cells (RBCs), Immunoglobulins, Albumin, Other
Plasma Products, Synthetic HBOC and PFC Agents, Recombinant Factors |
|
|
This volume of the Medical Imaging Markets series explores the world of
magnetic resonance imaging. This modality continues to generate growth as
applications expand and new "open" systems penetrate the market. |
|
|
The past 25 years have seen unprecedented advancements in the area of
women’s health. A number of events have helped to bring the concerns of
women’s health to the forefront of medicine but the most significant was the
women’s health movement, which increased attention to women’s health issues
and the shortcomings of traditional medical practice and research. |
|
|
This report provides and in-depth analysis of the market for
prescription drugs used in the treatment of gastrointestinal (GI) disorders,
such as nausea and vomiting, heartburn, gastro-esophageal reflux disease
(GERD), ulcer, cancers of the GI tract (colorectal, esophageal, and
gastric), Crohn’s disease, ulcerative colitis, irritable bowel syndrome
(IBS), diverticular disease, constipation, celiac disease, short bowel
syndrome, diarrhea, intestinal obstruction, and digestive enzyme disorders. |
|
|
This complete re-evaluation of the Men’s Health market focuses on the
following prescription drug treatment segments: Men’s Cancer, Men’s Sexual
Dysfunction, Men’s Sexually Transmitted Diseases, Men’s Urinary Conditions,
Andropause |
|
|
This second edition of Kalorama’s best-selling look at the clinical
contract research industry provides the key information competitors need to
navigate the complexities and costs of clinical research in the drug
development process. In addition to a comprehensive discussion of the market
and regulatory environment, the report details: |
|
|
The strategic interplay of of HIV/AIDS diagnostics and therapeutics is
one of the most complex that the healthcare industry has ever seen. In order
to cope with the challenges and opportunities of HIV/AIDS, companies must
think on a global basis, and in addition to the basic pathology and
complications of HIV/AIDS, there are societal and ethical pressures,
geopolitical factors, and evolving marketplace disruptions. |
|
|
Ophthalmology is entering one of the most remarkable phases in recent
history of this industry; new technologies and treatment modalities for both
visual acuity and major eye diseases may dramatically change the composition
and competitive dynamics of this market. As RK and LASIK changed the market
a few years ago, even newer competitive technologies are just now emerging.
From the advent of photodynamic therapy and new drug delivery techniques to
revolutionary surgical approaches to refractive vision correction,
ophthalmology is poised to see a plethora of new treatment options. |
|
|
The major indications for critical care are discussed as well as the
range of pharmaceutical products used in the critical care environment. The
strategic market characteristics of the critical care pharmaceuticals market
are also discussed. The trends —- cost-containment programs, restricted
formulary acceptance, clinical pharmacy, and the growth of the generic drug
population —- as well as their impacts on the clinical care pharmaceutical
markets are discussed. These are selected to assess the rationale for
intentionally targeting the critical care pharmaceuticals market in
hospitals alone and as part of an overall hospital pharmaceutical marketing
strategy. They are presented to provide the most informative picture of
potential market in this field. |
|
|
The field for glucose testing devices is crowded; worldwide, more than
50 companies market blood glucose monitors. The extraordinary market growth
fueled by the increasing numbers of diagnosed diabetics continues to attract
more entrants to the industry. Glucose self-testing has, therefore,
attracted a varied cast of players including: large multinational companies
such as Abbott Laboratories, Bayer Corp., LifeScan/Johnson & Johnson, and
Roche Diagnostics; insulin pump companies Medtronic/MiniMed, Disetronic; and
Animas and smaller device companies such as Home Diagnostics and Sontra
Medical Inc. |
|
|
The reinvigorated market for medical imaging systems employing x-rays
has undoubtedly been propelled by the explosion of digital technology. But
also, the expanded role of imaging modalities in a whole host of clinical
applications from trauma to cancer to cardiology has increased the profile
of radiography while enabling computer technologies expand the usefulness of
traditional x-ray techniques. |
|
|
The protein therapeutics sector is a story of triumphant science,
representing both life-saving treatments for millions and a multi-billion
dollar industry. This report details both the scientific and business
aspects of the protein therapeutics marketplace, including market size and
growth, competitive market share, geographical segmentation, top products,
and forecasts to 2010 for each of the following individual product areas:
|
|
|
The commercial world of medical sensors is vibrant and evolving rapidly.
Reports that are only a year or two old are already out-of-date as new
technologies make rapid penetration. This new edition attacks the field from
the point of view of current R&D, technology and innovation, with an eye to
potential markets and emerging technologies in clinical medicine, remote and
military applications, process and materials quality control, environmental
monitoring, and food and drug quality control. |
|
|
There are hundreds of drugs in Phase III clinical trials, of which
almost 200 of them may gain market approval from the FDA in the coming 5
years. Which drugs will make it and how these drugs impact existing
pharmaceutical markets in terms of overall size and competitive share is one
of the most difficult forecasting projects in market research. |
|
|
Adjunctive therapies are not only vital to the success of cancer
treatments, enhancing compliance and outcomes, but they are also a dynamic
area of research and development in a variety of disciplines from drug
delivery to biologics. It also happens to be the largest portion of the
overall cancer therapeutics market.
This report provides the reader with a comprehensive analysis of the
worldwide market for therapeutics to treat and manage symptoms in cancer
patients. Market information, including market size and growth, is provided
for 2003 to 2010 on various product subcategories |
|
|
The landscape of generic companies is changing: their relative might in
the industry is increasing and the product lines their offering are growing
in depth and breadth. Strong growth in the sector has come not only from
more aggressive tactics and better acceptance in the clinical and consumer
population, but by the loss of patent protection in the past few years of
some huge-name drugs, including Prozac, Zocor, Prilosec, Prevacid, Sporanox,
Evista, Flovent, Claritin, Allegra, Diflucan, Zofran, Zoloft, and Pravachol.
|
|
|
This report on the U.S. market for over-the-counter (OTC) pediatric
medications presents an in-depth analysis of the performance of
non-prescription pediatric drugs and other selected pediatric healthcare
products in the marketplace. The analysis captures the performance of the
market players, categories, and leading brands in terms of revenue growth
and volume growth in several categories of medication |
 |
Biopharmaceutical research and development is sure to dramatically
increase the number of injectable drugs coming to market over the next few
years. While advanced drug delivery techniques continue to hold promise for
unique methods of administration, the traditional injection is still the
dominant paradigm. However, the staggering costs and intransigent safety
problems associated with sharps, along with consumer demand and the move to
alternate-site care, are pushing for alternatives to traditional needles and
syringes faster than advanced delivery technologies can come online. |
 |
The private label over-the-counter (OTC) market has been gaining ground
rapidly over the past five years. The private label sector has shed its
image of being a ‘me-too’ version of national brands and worked toward
offering quality and innovation at an economical price. With benefits for
consumers, retailers, and manufacturers, private label healthcare should
experience solid growth through the end of the decade. |
 |
This report provides the reader with a comprehensive analysis of the
domestic and international markets involving pharmaceuticals to treat skin
diseases and disorders. This edition of Worldwide Market for Prescription
Dermatologic Drugs is the fifth time Kalorama Information has
comprehensively studied the dermatology markets. |
 |
The field of biotechnology instrumentation has been an expanding one
ever since the emergence of the Human Genome Project 20 years ago. Although
the filed certainly existed prior to that point in time, it was the Human
Genome Project with its major access to key universities, national
laboratories, and government funding sources that gave great acceleration to
the field. |
 |
The U.S. long-term care industry experienced strong growth from 1999
through 2004 and this growth is expected to continue through the end of the
decade. Indeed, the aging of the U.S. population will push unprecedented
demand for all forms of long-term care, but ongoing cost containment issues
continue to pressure both private and public managed care organizations and
make competition in this dynamic environment challenging. |
|
|
In the Spring of 2003, Kalorama published its first report on
Outsourcing in Drug Discovery. Since then, so much has changed, the use of
the term "2nd Edition" hardly seems appropriate. This new study involved
completely re-examining the market from the ground up.
|
|
|
With the mapping of the human genome and the concomitant explosion of
proteomics, a steady stream of biopharmaceuticals have been
launched—recombinant therapeutic proteins, monoclonal antibody-based
products used for therapeutic or in vivo diagnostic purposes, and nucleic
acid-based products. |
 |
The U.S. Market for OTC anti-infective products surpassed the $2 billion
mark last year. Although overall growth is sluggish, the market is a proven
revenue source for a number of major brands, and there have been some nice
surprises in the performance of some categories, such as first-aid related
antiseptic and antibiotic products. |
 |
This completely updated 2nd edition to Kalorama’s popular 2003 study
focuses on the market applications of current and advanced drug delivery
technology to the development of new and modified pharmaceutical products in
the United States. |
 |
There has not been a year in the last decade in which the IVD market in
China has failed to grow. With a gross domestic product of over $1.4
trillion, China surpassed Italy last year to become the world’s sixth
largest economy, according to the International Monetary Fund. This country
of 1.3 billion people is now America’s sixth largest export market, and
China’s economy, which has been growing at an average rate of 8% over the
last 20 years, grew over 9% last year. |
|
|
Some of the biggest-selling biological drugs developed during the first
phase of the biotechnology revolution in the 1980s, including human growth
hormone (hGH) and insulin, are set to lose patent protection in the United
States in 2005 and soon after. |
 |
Respiratory diseases are among the most common ailments across the
world. Asthma and chronic obstructive pulmonary disease (COPD) are the major
causes of mortality rates among children and elderly. Currently, about 300
million people suffer from asthma—the number only expected to rise over next
few years—and about 14.2 million people suffer from COPD. |
|
|
Although, the next 15-20 years will shift a majority of the population
into the elderly population group, children will continue to remain the bulk
of the dependent population worldwide with 9 in every 10 people falling into
a pediatric age range in the less developed regions of Africa, Asia and
Latin America. Therefore, the treatment of conditions and diseases affecting
pediatrics and the healthy growth of children are vital to providing a solid
foundation for healthy adults in the future. |
 |
Information technology (IT) has the potential to improve the quality,
safety and efficiency of clinical care. IT is not new to the hospital
setting. Computers and software have been used for many years to improve the
paper-based administrative functions of hospital support staff, such as
scheduling and billing. But the use of IT in the clinical setting to
optimize, streamline and simplify patient records, testing, imaging and
operating room procedures has lagged behind its medical administrative
applications. |
 |
Cancer, with its high prevalence and mortality rate, continues to rank
among the world's deadliest and most costly diseases. According to the WHO,
in 2003, about 25 million people live with cancer and nearly 11 million new
cases are diagnosed each year. |
 |
One of the keys to understanding many complex biological interactions,
is the role played by specific carbohydrates. This is glycobiology. While
many glycobiology-related products commercialized to date are detection and
analysis kits for analyzing glycoproteins and the extent of glycosylation, a
newer body of research is harnessing glycobiology to develop glycol-based
drugs, or glycotherapeutics. |
 |
In the industrial world, over 240 million people lack one or more teeth.
It is estimated that 40% of the western population is missing one tooth or
more. In the United States, approximately 10% is the population is totally
edentulous, and every year about two million Americans loose a tooth due to
sporting accidents. |
 |
This report considers the markets for therapeutic cardiovascular
devices, such as prosthetic valves, pacemakers, stents, support devices,
ICDs, VADs, and TAHs, in the United States as broken down into four major
segments: cardiomyopathy/congestive heart failure, arrhythmias,
arteriosclerosis (coronary artery disease), and valvular heart disease |
 |
Management of both acute and chronic neurologic diseases can be
challenging for both the patient and the health care provider. Many
neurologic disorders involve progressive deterioration in physical and
mental capabilities, which can be devastating to the patient and the
patient’s family. |
 |
Surgical and trauma wounds are, by far, the most common types of wounds
addressed in the wound care area, but it is by no means the easiest to
compete in. There are millions of surgical procedures performed annually
worldwide; in the United States alone, there are over 100,000 surgeries
performed daily. |
 |
Neurological disease that impacts the sensory pathway can produce severe
chronic pain, also known as neuropathic pain. This usually is unrelated to
any peripheral tissue injury. This occurs with disorders of the central
nervous system (CNS), such as stroke and multiple sclerosis, or with
conditions associated with peripheral nerve damage, such as mechanical
injury, diabetic neuropathy or herpes zoster infection. |
 |
This market briefing concentrates on the U.S. market for medical
nutritional support—in particular, the enteral and parenteral foods. The
continuing development of equipment, medical foods, and feeding procedures
that secure the nutrition of critically ill patents has greatly improved
recovery and survival in select populations. |
 |
Approximately 27 million burn cases requiring professional treatment
occur worldwide each year, and of these 7 million will require
hospitalization and more than a million will die as a direct result of their
burns. Burn injuries are a particularly difficult and painful area of
medicine requiring multi-pronged approach to address infection, pain, and a
host of long-term complications. |
 |
This report on the U.S. market for over-the-counter (OTC) cough, cold,
sinus and allergy (CCSA) medication presents an in-depth analysis of the
performance of various CCSA drugs in the U.S. market. The analysis captures
the performance of the market players, drug categories, and leading brands
in terms of revenues and growth. |
 |
The aging of the population and continued advances in biotechnology
drive the skin ulcer portion of the wound care industry, estimated at $3.3
billion globally. A lack of effective treatment options has heretofore added
to the increased costs of skin ulcer treatment and has contributed to the
growing frustration in the industry. |
http://www.bioportfolio.com/cgi-bin/acatalog/sitemap.html
| |
|
